Zanubrutinib and Venetoclax for Relapsed / Refractory CLL - Dr. Matthew Davids and Dr. Inhye Ahn

29 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
An ongoing phase 2 clinical trial is evaluating the efficacy and tolerability of fixed-duration zanubrutinib plus venetoclax for relapsed / refractory CLL. Early clinical activity and safety data are promising thus far.

Dr. Inhye Ahn from Dana-Farber Cancer Institute and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting 2024.

Read the full article on CLL Society's website at: https://cllsociety.org/2025/08/zanubrutinib-and-venetoclax-for-relapsed-refractory-cll/
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook: https://www.facebook.com/CLLsociety
Twitter: https://twitter.com/CllSociety
LinkedIn: https://www.linkedin.com/company/cll-society/
Categoria
Oncology
Commenta per primo questo video.

Prossimo